New England Journal of Medicine publishes positive Phase 3 Dupixent (dupilumab) results in children with moderate-to-severe asthma Dupixent significantly reduced severe asthma attacks and improved
/PRNewswire/ Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing.
Dupixent (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease Pivotal